Exane Derivatives’s Capital One COF Stock Holding History

Exane Derivatives’s Portfolio COF Stock Details COF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-245	Closed	-$35.5K	–	1029
2021 Q4	$35.5K	Buy	+245	New	+$37.9K	0.01%	538

Other funds holding COF

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.7B AUM 13.92% 1-Year Est. Return

Exane Derivatives's COF Position: Q1 2022 in Review

Exane Derivatives sold out of Capital One (COF) in Q1 2022, closing a stake of 245 shares — an estimated $35.5K sold.

Exane Derivatives first reported a position in COF in Q4 2021 and held it in 1 quarter. The position peaked at $35.5K in Q4 2021. 1,092 funds tracked by Wall St. Rank hold COF as of Q1 2022.

Exane Derivatives reported no remaining Capital One position as of Q1 2022 after selling out during the quarter.
Exane Derivatives sold 245 Capital One shares in Q1 2022, an estimated $35.5K.
Exane Derivatives first reported a position in Capital One in Q4 2021 and held it in 1 quarter.
Exane Derivatives's Capital One position peaked at $35.5K in Q4 2021.
1,092 funds tracked by Wall St. Rank held Capital One as of Q1 2022.

Based on Exane Derivatives's 13F filing for Q1 2022, filed 22 Apr 2022.